We demonstrated that intermediate or high PD‐L1 expression (PD‐L1 TPS ≥20%) in patients with EGFR‐mutated NSCLC was associated with early resistance to osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.